Table 1.

Overview of therapeutic options for patients with omHSPC.

Treatment option	Abiraterone	Apalutamide	Enzalutamide	Docetaxel	Local treatment	MDT
Suitable for omHSPC	+	+	+	+	+	+
Suitable for synchronous disease	+	+	+	+	+	?
Suitable for metachronous disease	?	+	+	?	–	+
Studies	LATITUDE;6 STAMPEDE13	TITAN14	ENZAMET;15 ARCHES16	STAMPEDE;17 CHAARTED;5,18 GETUG-AFU 1519	STAMPEDE (RT);20 NCT02742675 (RP, no survival data)21	ORIOLE (no survival data)22
Definition of patients with omHSPC	Low-risk LATITUDEa Low-risk LATITUDEa and Low-volume CHAARTEDb	Low-volume CHAARTEDb	Low-volume CHAARTEDb	Low-volume CHAARTEDb Low-volume CHAARTEDb Low-volume CHAARTEDb	Low-volume CHAARTEDb ≤5 bone or extrapelvic lymph node metastases and no visceral metastases	Recurrent disease, with up to 3 metastases

MDT = metastasis-directed therapy; omHSPC = oligometastatic hormone-sensitive prostate cancer.

^aNot high risk (≥2 high-risk features of ≥ 3 bone metastasis; visceral metastasis; ≥ISUP grade 4).

^bNot high volume (≥4 bone metastasis including ≥1 outside vertebral column or spine or visceral metastasis).